Clinical trial

Immunological Basis for Mepolizumab Activity in COPD

NCT05320939

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2023-04-01

PhasePHASE2

Study timeline

Study start (estimated)2023-04-01Date precision: month

Registry last updated2023-04-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

COPDverified · MONDO: chronic obstructive pulmonary disease

Interventions

Mepolizumab 100 MGDRUG · verified · RxNorm: mepolizumab 100 MG

Sponsors & collaborators

Temple Universitylead sponsor

GlaxoSmithKlinecollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05320939 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.